Hybrid Event | D2R Investor Series Transform your science into a new Biotech company - Investment Insights with Medicxi

Every year, billions of dollars are invested by funding agencies in basic and translational research, yet the path from academic discovery to private investment necessary for the creation of new companies is rarely straightforward. In this seminar, you'll get an inside look at how investors work, what makes a research idea stand out to venture capitalists, and how they evaluate translational value of scientific opportunities. By the end of the session, you’ll have a clearer grasp of the framework needed to transition an idea or mechanism discovered in the lab to an investment phase.

This event is can be attended in-person at D2R Offices (1010 Sherbrooke St. West, Suite 1800 (18th floor) OR virtually on Zoom.

About the Speaker

Marco Prunotto 

Marco is a Venture Partner at Medicxi. Prior to joining Medicxi, Marco was Global Head of Technology and translational research at Roche Pharma I20 development where he was part of the leadership team. He previously served as Head of Translational Research at Galapagos NV. Prior to that he served in several roles within the discovery organisation of Roche pRED in Basel. He created and led the phenotypic drug discovery unit and led the nephrology discovery team. Marco received a PhD in Biotechnology from the University of Turin and conducted postdoctoral research at the University of Geneva. Marco also serves as senior lecturer at the School of Pharmaceutical Sciences of the University of Geneva.

Register

Be part of the discussion with Medicxi

Confirmation emails will be provided to registered participants a few days before the event.